Dr. Andrew D. Seidman on the Lack of a Biomarker in Certain Breast Cancers

March 1, 2016
Andrew D. Seidman, MD

Seidman says currently there is not a HER2 histochemical test for gene amplification or signatures to best select patients for either CDK46 or MTOR inhibitor, as well for PI3 kinase inhibition.

Andrew D. Seidman, MD, attending physician, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses the present lack of a biomarker for targeted therapies in patients with ER-positive, HER2-negative metastatic breast cancer. Seidman says currently there is not a HER2 histochemical test for gene amplification or signatures to best select patients for either CDK46 or MTOR inhibitor, as well for PI3 kinase inhibition.

Seidman says these biomarkers could help in selecting patients for the best targeted therapies available for their particular cancers.